CRISPR-Cas9-mediate TRAC KO therapies, including CD19-targeting CTX110 (NCT04035434) and TyU19 (NCT05859997), CD19/CD20-targeting CTA101 (NCT04227015), and CD7-targeting WU-CART007 (NCT04984356) targeting CD7, also effectively prevented GvHD [70, 72–74]. The gene discussed is CD7; the disease is graft versus host disease.